Azurity 污污漫畫s鈥� Nymalize (nimodipine) oral solution in a 30mg/5ml prefilled ENFit syringe has received US Food and Drug Administration (FDA) approval.
The ready-to-use prefilled syringe offers an additional layer of security for both patients and healthcare professionals when administering medication.
The oral solution in the prefilled ENFit syringe offers an effective alternative for adult subarachnoid haemorrhage patients who are unable to swallow capsules.
The adoption of ENFit connectors, which are recommended by the FDA, is said to be on the rise, with around 60% of acute care facilities in the US making the switch from traditional nasogastric tubing.
Nymalize improves neurological outcomes by reducing the incidence and severity of ischemic deficits in adults with subarachnoid haemorrhage from ruptured intracranial berry aneurysms.
It is suitable for patients across a range of post-ictus neurological conditions, classified from Hunt and Hess Grades I to V.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe Nymalize prefilled ENFit syringes (30 mg/5 ml), along with prefilled oral syringes (30 mg/5 ml and 60 mg/10 ml) and 8 oz (237 ml) bottles will soon be available for order through pharmaceutical wholesalers.
Azurity 污污漫畫s CEO Richard Blackburn stated: 鈥淧atients are our priority, and our purpose is to bring them new formulations and delivery systems that help them benefit from established medicines.
鈥淒elivering Nymalize with ENFit syringes may offer patients and healthcare professionals a more secure, reliable drug administration through standardisation.鈥�
In September 2022, the FDA granted approval for Azurity鈥檚 Konvomep (omeprazole and sodium bicarbonate for oral suspension) to treat active benign gastric ulcers.
